Roche "Revisiting" Safety Evaluation Post Posicor and Tasmar
Executive Summary
Roche is "revisiting" its safety evaluation processes for new drugs following the worldwide withdrawal of Posicor (mibefradil) and the European suspension of Tasmar (tolcapone) in the second half of 1998, Roche CEO Franz Humer said during the firm's annual financial results meeting in Basel, Switzerland on March 30.